Member Info for crumbs

Just off to work :) hopefully some good scancell RNS's on their way

Well obviously BioNtech themselves are seeing it! :) that research paper is from Dec 2018... so recent and will be presented by a BioNtech guy at some neoantigen event in April...maybe by then he can add something about 'a different approach'.... see Lindys work really is very novel... it does seem like they will all try everything else to exhaustion before coming to her and going ''ok we will give your ways a go now' .... but the thing is this whole neoantigen area is where it is at ... it is really hot.....Genentech now going up against their mates BioNtech because they do not need BioNtech to manufacture TCRs but they do need neoantigen targets! And ones that actually work are obviously not easy to find.... throw in cytotoxic CD4 cells and fact only scancell are patented to use the moditope approach and you start to see if moditope works you can throw all your AI approaches of imaging new neoantigens out the window we have a practical way of finding them because we understand cancer cells are stressed and due to that they give themselves away

Research..... moditope can do what no one seems able to?

Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cell line CT26. A comprehensive immune reactivity screening of 2474 peptides covering 628 transcribed CT26 point mutations was conducted. All tested treatment regimens were found to induce a single significant CD8+ T-cell response against a non-synonymous D733A point mutation in the Smc3 gene. Surprisingly, even though Smc3 D733A turned out to be the immune-dominant neoepitope in CT26 tumor bearing mice, neither T cells specific for this neoepitope nor their T cell receptors (TCRs) were able to recognize or lyse tumor cells. Moreover, vaccination with the D733A neoepitope did not result in anti-tumoral activity despite induction of specific T cells. This is to our knowledge the first report that neoepitope specific CD8+ T cells primed by tumor-released antigen exposure in vivo can be functionally irrelevant.

Yes of course! Same as the whole having to do CI combos... the real result is to get scancells techs recognised and eventually the penny drops..... hmm maybe scancell have it boxed with their 2 cancer vaccine platforms... We have to play the game as it exists to finally to change the rules.... data data data

Competition is good... that is what I'm getting AT... the TCR scene is hotting up!... what can BioNtech do?.... a deal with scancell maybe?... then quick to trial

They have the money for it and the manufacturing capabilities.. and they are always saying they want to be first... it is a very hot area,,, don't think LD is that hot on it though lol... she thinks why do all that when an off the shelf moditope vaccine or combo of modi vaccines can do it all :).... think Genentech pushing will do no harm though... what are BioNtech going to do now..... another big rival arrived on that scene

It is called moditope... have you not heard of it?

'The partnership’s focus on neoantigens will also have a potential advantage in that these targets exist universally across cancer types. That means neoantigen-directed T-cell therapies could possibly be used in many different cases, including in solid tumors. This approach represents a natural progression in the personalization of cancer immunotherapy, says Mellman. “We know how critical neoantigens are, and we think neoantigen-directed T-cell therapies have the potential to be an incredibly effective way of reshaping a person’s immune system to fight cancer.”

I'm not sure anything with the Lilly collaboration is happening... 4 years old and no trial.. remember BioNtechs TCR platform

'We have a vast and diversified portfolio of immune receptor candidates:
• More than 160 functionally validated TCRs against 20 different oncology targets.
• More than 60 different T-cell epitopes identified.'

'We are in preclinical development with our lead candidate, a CAR that targets an antigen frequently expressed in ovarian, endometrial and lung cancers. Clinical testing is expected to start in 2017'
https://biontech.de/wp-content/uploads/2016/03/CellGene.pdf

No trial... nothing more heard from them or Lilly.... yet they have to get scancell in to use moditope... I think it is not so easy get this tech to get T cells to target cancer effectively...

Think the race is on... so far do not think there has been much success in TCR trials... Adaptimmune come to mind... well you need T cells to target cancer... imagine CD4 cytotoxic t cells!

Genentech are getting into TCR... going up against BioNtech and not partnering with them on that platform...

Cell therapies vary in their specifics, but the general concept is the same: a specific subset of a person’s immune cells, called T-cells, are extracted, modified, multiplied and reintroduced into the body to attack and destroy tumor cells. For neoantigen-directed T-cell therapies, this means genetically engineering a person’s T-cells with receptors that recognize their own tumor-specific neoantigens. The BIG CHALLENGE, though, is choosing the right neoantigen to target for each patient, and the right receptor to target those specific neoantigens. Each person’s T-cells carry an incredibly diverse and unique collection of receptor types that are generated to recognize foreign cells.

“This is the reason we are looking to partner with Adaptive Biotechnologies,” says Don O’Sullivan, Ph.D., Global Head of Oncology Business Development. “They truly are the leaders in the identification of T-cell receptors (TCRs) specific to neoantigens. Their proprietary sequencing platforms and neoantigen-TCR matching technology are essential in making neoantigen-directed T-cell therapies a possibility.”

https://www.gene.com/stories/a-new-age-for-neoantigens

“The rate of discovery in this space is shocking,” says Ira Mellman, Ph.D., Vice President, Cancer Immunology. “In just the last year the number of immunotherapy targets has increased by 30 percent, and there are now more than 3,300 agents under clinical or pre-clinical investigation.”

Within this enormous body of research, Genentech scientists have zeroed in on one particular area — neoantigens, proteins generated by tumor-specific mutations — that could have significant potential in treating cancer. Tumor cells share a majority of their DNA with healthy cells, but looking deeper, there are areas where tumor DNA is distinct. It’s these differences, which manifest as neoantigens, that offer a ‘seek-and-destroy’ signal for our immune systems to home in on.

I'll be feeling asleep I hope :) dreaming of £20 billion mcaps though

Also what if the data your entering is wrong or just too incomplete...

Strange thing... on BioNtechs up to date pipeline graphic... no Lilly showing as a partner on Cell therapies... might not mean anything or might, it does not seem their partnership from 2015 has managed to bare any fruits...all other partners old and very new showing on all other parts of the pipeline

https://biontech.de/pipeline-patients/

Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers.

The companies will combine Genentech’s noted immunotherapy research and medications with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform TruTCR to accelerate a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer, the company announced this morning.

https://www.biospace.com/article/adaptive-biotechnologies-and-genentech-launch-personalized-cancer-care-program-worth-more-than-2-billion/

And CI inhibitors are limited in the amount of patients and cancers they can target... as you can see Merck are throwing them at everything! ... with varying success... moditope will target pretty much all cancer targets .... again patent landgrab:)) ... once you understand that you will get moditope could become an industry of a platform... but scancell have more ImmunoBody and now the Glyca mabs... 30 mill mcap... I do not think soooo lol

Yes, scancell is offering a totally new approach..'novel'... Merck is relying on Keytruda a PD1 checkpoint inhibitor... it is not a therapy or an approach unique to Merck or any one pharma in fact they pay BMS a percentage of each sale due to patent infringement https://www.fiercepharma.com/pharma/merck-to-pony-up-625m-plus-keytruda-royalties-to-settle-bms-ono-patent-fight

Scancell will completely own the moditope aproach ...patent landgrab :)))

https://www.cancer.org/latest-news/fda-approves-vitrakvi-larotrectinib-for-tumors-with-certain-genetic-change.html
"Today’s approval marks another step in an important shift toward treating cancers based on their tumor genetics rather
than their site of origin in the body," said FDA Commissioner Scott Gottlieb, MD. "This new site-agnostic oncology therapy isn’t specific to a cancer arising in a particular body organ, such as breast or colon cancer. Its approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine. We now have the ability to make sure that the right patients get the right treatment at the right time.”

The FDA based its approval on 3 clinical trials that included 55 adults and children with several different cancer types, all with NTRK positive tumors. The patients’ tumors could not be removed through surgery or had gotten worse after treatment.

All the patients were given Vitrakvi, which comes in pill form. The overall response rate, which is the portion of patients whose tumors shrank, was 75%. The improvement lasted for at least 6 months in 73% of those who responded, and for at least a year in 39% of those who responded.

Vitrakvi was approved using several FDA approaches designed to speed up the availability of drugs to treat serious diseases – breakthrough therapy designation, priority review status, and accelerated approval. It was also granted orphan drug designation, which provides financial incentives to encourage the development of drugs for rare diseases.

Common side effects included fatigue, nausea and vomiting, cough, constipation, diarrhea, and dizziness. Regular blood tests are needed to check liver function. Women who are pregnant or breastfeeding should not take Vitrakvi. Patients should report signs of neurologic reactions such as dizziness.

Vitravki is marketed by Bayer and Loxo Oncology, Inc.

Yeah but just $8 billion upfront ... for T cell the cat

Eli Lilly splashes out $8 billion for onco assets ... hot hot hotter

https://www.ft.com/content/b3dbd986-1272-11e9-a581-4ff78404524e